Co-Host: Robert Svatek, MD

At the conclusion of these activities, participants will be able to:

1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.

2. Describe the mechanism of action of immunotherapy regimens.

3. Identify and manage the adverse events related to these agents.

CME Available: auau.auanet.org/node/26071

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma